Synovate Healthcare has announced the acquisition of US research firm Oncology Inc., which provides oncology treatment information from 100,000 patients to pharmaceutical, biotech and financial companies.
Oncology Inc.’s suite of proprietary research solutions will now be incorporated into Synovate Healthcare’s global oncology portfolio.
Oncology is already Synovate’s single largest therapy area, with offerings including the Global Oncology Monitor – covering drug treatment across the US, Europe, Asia Pacific and Japan – and a very large element of custom research. The new buy means that Synovate Healthcare can offer clients a customisable electronic ‘longitudinal’ patient diary study, additional physician panels, a PDA (handheld) platform and other custom research solutions, as well as additional patient samples for rare tumour types.
Synovate Global CEO Adrian Chedore says the move ‘demonstrates Synovate’s commitment to investing in our healthcare portfolio.’ According to Synovate Healthcare CEO Michael Spedding, ‘This development is a clear step towards our strategic vision for this treatment area: to become the full-service oncology market research agency of choice. Combining the two offerings represents a marriage between time-tested expertise and exciting new approaches.’
John Fair, Oncology Inc.’s Vice President of Sales and Client Service, says his firm’s ‘offering and culture are a natural fit with those of Synovate’.
Synovate Healthcare employs over 500 healthcare market research professionals across Europe, US, Asia Pacific and Japan and offers global fieldwork capabilities. Web sites: www.synovate.com/healthcare